These prospectively validated, conventional biomarkers of high-risk CLL, particularly del(17p) as well as IGHV and TP53 mutational status, continue to find relevance in contemporary clinical practice, and are featured within widely used prognostic indices such as the CLL International Prognostic Index (CLL-IPI) (28). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.